Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug Administration a little more than a week after he left the agency.

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who appointed Prasad to the CBER position in May. Endpoints first reported his return on Saturday, and that was confirmed by the FDA shortly thereafter.

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson, marking the latest twist in an unusual run leading the FDA office overseeing vaccines and gene therapy.